Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08CJM
|
|||
| Former ID |
DIB005182
|
|||
| Drug Name |
Peptide YY 3-36
|
|||
| Synonyms |
YY 3-36; Peptide YY 3-36 (oral, eligen)
Click to Show/Hide
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 2 | [1] | |
| Company |
Emisphere Technologies Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Peptide tyrosine tyrosine PYY (PYY) | Target Info | Modulator | [2] |
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCR ligand binding | |||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00537420) A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Emisphere. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.